The $315 Pill That Could Change Everything: FDA Approves First Oral Drug That Slashes Cholesterol by 60%

 

The $315 Pill That Could Change Everything: FDA Approves First Oral Drug That Slashes Cholesterol by 60%

**For the first time in history, patients can get injectable-level cholesterol reduction from a once-a-day pill. The era of the needle may finally be over.**

---

## Introduction: The End of the Needle

For more than a decade, the most powerful cholesterol-lowering drugs have come with a catch: they required a needle. Injectable PCSK9 inhibitors like Amgen's Repatha and Regeneron's Praluent have been available since 2015, offering dramatic reductions in "bad" LDL cholesterol. But they've never achieved widespread adoption. The reasons are familiar: high prices, insurance hurdles, and patient reluctance to use injectable drugs.

That all changed on July 16, 2026.

The U.S. Food and Drug Administration approved **Lipfendra (enlicitide)** , the first-ever oral PCSK9 inhibitor, for adults with high cholesterol. It's a once-daily pill that can slash LDL cholesterol by up to 60%—far beyond what statins can achieve. And it's a fraction of the cost of existing injectable alternatives.

For the first time, patients can get injectable-level cholesterol reduction from a pill they can take at home.

---

## The Numbers That Matter: A 60% Plunge in "Bad" Cholesterol

To understand why this approval is such a big deal, you have to understand the numbers.

About **one in four adults in the U.S.** have high LDL cholesterol, according to the American Heart Association. For years, the standard of care has been statins—drugs that block an enzyme the liver uses to make cholesterol. Statins work, but they have limits. Even at the highest doses, many people need additional help lowering their LDL enough to meet medical guidelines.

Lipfendra can take them the rest of the way.

In two Phase 3 clinical trials involving **3,207 adults** with severe hypercholesterolemia—including those with an inherited condition called heterozygous familial hypercholesterolemia (HeFH)—the results were striking.

| Trial Population | Baseline LDL | LDL Reduction vs. Placebo |

|------------------|--------------|---------------------------|

| **High-risk/ASCVD patients** | 96 mg/dL | **-56%** |

| **HeFH patients** | 119 mg/dL | **-59%** |

In plain English: **Lipfendra reduced "bad" cholesterol by 56% to 59% compared to placebo.**  In a post-hoc analysis, the reduction reached **60%** in some patients.

The drug also lowered other dangerous lipids, including non-HDL cholesterol by up to 54% and apolipoprotein B by up to 50%.

**The bottom line:** Lipfendra can take patients to cholesterol levels that were previously only achievable with expensive, inconvenient injectable drugs—or not achievable at all.

---

## How It Works: The PCSK9 Pathway

To understand why Lipfendra is such a breakthrough, you need to understand the biology.

Your liver produces a protein called **PCSK9** that essentially destroys the LDL receptors on the surface of your liver cells. Those receptors are responsible for clearing "bad" cholesterol from your blood. The more PCSK9 you have, the fewer receptors you have, and the more cholesterol stays in your bloodstream.

Lipfendra is a **macrocyclic peptide**—a molecule designed to bind to circulating PCSK9 and block its interaction with the LDL receptor. By blocking PCSK9, it prevents the destruction of LDL receptors, allowing more receptors to remain on the surface of liver cells to clear LDL-C from the blood.

In other words: **Lipfendra unblocks your body's natural cholesterol-clearing machinery.**

This is the same mechanism used by injectable PCSK9 inhibitors that have been available for more than a decade. But those drugs require injections and have list prices that can exceed $500 to $600 per month. Lipfendra is a pill you take once a day—and it costs **$315 for a 30-day supply.** 

---

## The Price Point: A Game-Changer for Access

One of the biggest barriers to PCSK9 inhibitors has been cost. Injectable PCSK9 drugs like Repatha and Praluent have list prices that can exceed $500 to $600 per month, and while insurance coverage has improved, many patients still face high copays or prior authorization hurdles.

Lipfendra's list price is **$315 per month**—roughly half that of the injectable alternatives.

**The drug will be available in a matter of weeks,** according to Merck.

The lower price point could dramatically expand access. As RBC Capital Markets analyst Trung Huynh noted, "an estimated 70% (and more) of eligible high-risk atherosclerotic cardiovascular disease patients remain undertreated; driven by injection aversion, prior authorization burden, and limited specialist access in primary care."

For patients who have been taking injectable PCSK9 inhibitors, the switch to a cheaper, more convenient pill is almost inevitable. For patients who couldn't afford the injectables, Lipfendra could be the first time they can access this level of cholesterol reduction.

---

## The Human Element: What This Means for Patients

### For the Patient Who Can't Tolerate Statins

Up to 10% of patients experience muscle pain or other side effects from statins. For them, the options have been limited. Lipfendra offers a completely different mechanism—and it can be used in patients who are already taking statins, or potentially as an alternative for those who can't tolerate them.

### For the Patient with Familial Hypercholesterolemia

HeFH is an inherited condition that causes extremely high cholesterol levels from birth. Patients with HeFH often have LDL levels above 190 mg/dL and are at dramatically increased risk of early heart attacks. In the HeFH trial, patients had an average baseline LDL of 119 mg/dL—even while already taking maximally tolerated statin therapy. Lipfendra lowered their LDL by 59%.

### For the Patient at High Risk

For patients who have already had a heart attack or stroke—or who are at high risk for one—the new AHA/ACC guidelines recommend LDL targets below 70 mg/dL. In the high-risk trial, patients taking Lipfendra saw their LDL drop from 96 mg/dL to well below that threshold.

### For the Patient Who Hates Needles

This one is simple. Some patients simply don't want shots. Lipfendra eliminates that barrier entirely.

As Dr. Christopher Cannon, a cardiologist at Brigham and Women's Hospital in Boston, told The New York Times: **"I'm thrilled."** 

---

## The Catch: Fasting Requirements and Side Effects

No drug is perfect, and Lipfendra has its limitations.

**The fasting requirement is strict.** The pill must be taken on an empty stomach. Patients must take the tablet in the morning and avoid food for a period after dosing.

**The side effects are mild.** In the high-risk trial, the frequency of adverse reactions was similar between those treated with Lipfendra and those receiving placebo. In the HeFH trial, the most common side effects occurring at higher frequencies than placebo were **diarrhea and dizziness.** 

**The big unknown:** While the trials showed that Lipfendra provides significant reductions in atherogenic lipoproteins, **it is not yet known if the treatment can reduce the risk of cardiovascular morbidity and mortality.**  Merck is conducting ongoing trials to determine whether the drug can actually prevent heart attacks and strokes. This is a critical distinction: lowering cholesterol is a surrogate endpoint; preventing cardiovascular events is the real goal.

---

## The Bigger Picture: What This Means for Merck

For Merck, Lipfendra is more than just a new drug—it's a **strategic lifeline.**

The company's blockbuster cancer treatment Keytruda is set to lose key patent protections starting in 2028, exposing the company to competition from biosimilar versions. Keytruda has been one of the world's top-selling medications for years. The company desperately needs new revenue streams to fill the gap.

Lipfendra could be that revenue stream. Analysts project peak sales of **$3.5 billion to $5 billion** by the early 2030s. Some have suggested "tens of billions of dollars" in potential. Merck shares rose 4% on the approval news.

The drug also received a **Priority Review** designation and was part of the FDA Commissioner's National Priority Voucher program, which is intended to slash review periods for drugs that are critical to public health or national security.

**Lipfendra is Merck's best hope for replacing Keytruda's revenue.** And with a pill that's cheaper, more convenient, and just as effective as injectable alternatives, it has the potential to reshape the entire cholesterol management market.

---

## What This Means for the Cholesterol Drug Market

### The Injectable PCSK9 Market Is in Trouble

Injectable PCSK9 inhibitors have been on the market for more than a decade, but they've never achieved the blockbuster sales that analysts once predicted. The reasons are clear: high prices, insurance hurdles, and patient reluctance to use injectable drugs.

Lipfendra addresses all three problems. It's cheaper (roughly half the price), it's a pill (no needles), and it's more convenient. **For patients who have been taking injectable PCSK9 inhibitors, the switch to a cheaper, more convenient pill is almost inevitable.**

### The Statin Market Is Under Pressure

Statins have been the standard of care for cholesterol management for decades. They're cheap, generic, and effective. But they can only lower LDL by about 30-50% at maximum doses. For patients who need to get below 70 mg/dL, statins alone often aren't enough.

Lipfendra is a **complement**, not a replacement, for statins. It's approved for use in patients who are **already taking maximally tolerated statin therapy.**  But it could also be used as an alternative for patients who can't tolerate statins—and that could put pressure on the statin market over time.

### The Oral PCSK9 Era Has Arrived

Lipfendra is the first oral PCSK9 inhibitor, but it won't be the last. AstraZeneca is developing its own oral PCSK9 candidate, laroprovstat, which is still in Phase III trials. Merck's approval validates the entire class. **Within five years, the PCSK9 market could shift from injectables to pills.**

---

## Frequently Asked Questions

### Q: What is Lipfendra?

Lipfendra (enlicitide) is the first oral PCSK9 inhibitor approved by the FDA. It's a once-daily pill that lowers "bad" LDL cholesterol by up to 60%.

### Q: How does it work?

Lipfendra blocks the PCSK9 protein, which normally destroys LDL receptors on liver cells. By blocking PCSK9, it allows more LDL receptors to remain on the surface of liver cells to clear cholesterol from the blood.

### Q: How much does it cost?

Lipfendra has a list price of **$315 for a 30-day supply**—roughly half the cost of injectable PCSK9 inhibitors.

### Q: Who is it for?

Lipfendra is approved for adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH), who are already taking maximally tolerated statin therapy.

### Q: How effective is it?

In clinical trials, Lipfendra lowered LDL cholesterol by **56% to 59%** compared to placebo.

### Q: Does it have side effects?

The most common side effects are **diarrhea and dizziness**. Adverse event rates were similar between Lipfendra and placebo in the main trial.

### Q: Does it require fasting?

Yes. Patients must take it on an empty stomach.

### Q: Can it prevent heart attacks?

We don't know yet. While the drug lowers cholesterol, Merck is conducting ongoing trials to determine if it can reduce the risk of cardiovascular morbidity and mortality.

### Q: Is it better than statins?

It's different. Lipfendra works through a completely different mechanism than statins. It's not a replacement for statins—it's approved for use in patients already taking statins. But it can lower cholesterol far below what statins can achieve alone.

### Q: When will it be available?

Merck says the drug will be available in **a matter of weeks.** 

---

## Conclusion: A New Era in Cholesterol Management

The FDA approval of Lipfendra is a watershed moment in cardiovascular medicine. For the first time, patients have access to a once-daily pill that can lower "bad" cholesterol by up to 60%—matching the power of expensive injectable drugs at half the cost.

**This is not just a new drug. It's a new paradigm.**

Statins have been the backbone of cholesterol management for decades. They're effective, but they have limits. For millions of patients who can't reach their LDL targets—or who can't tolerate statins at all—Lipfendra offers a completely new path forward.

The drug works through a different mechanism than statins. It's a pill, not an injection. It's half the price of injectable alternatives. And it will be available in a matter of weeks.

Of course, there are caveats. The fasting requirements are strict. We don't yet know if the drug can actually prevent heart attacks and strokes. And the drug's effectiveness in "real-world" patients—outside the controlled environment of clinical trials—remains to be seen.

But for patients who have been waiting for a better option—who have struggled with statin side effects, who couldn't afford injectable PCSK9 inhibitors, or who simply couldn't get their cholesterol low enough—Lipfendra is a game-changer.

As one patient advocacy group put it: **"We are encouraged by the approval of a new oral PCSK9 inhibitor option for adults who need additional LDL-C lowering."** 

The era of the injectable PCSK9 inhibitor may be ending. The era of the oral PCSK9 inhibitor has just begun. And for millions of Americans at risk of heart disease, that's a development worth celebrating.

---

## Disclaimer

**IMPORTANT:** This article is for informational and educational purposes only and does not constitute medical advice. Lipfendra (enlicitide) is a prescription medication that should only be taken under the supervision of a qualified healthcare provider. The information contained herein is based on publicly available sources and reflects the author's understanding as of the publication date. Drug pricing, availability, and clinical trial data are subject to change. You should consult with your doctor or other qualified healthcare professional before starting, stopping, or changing any medication.

---

*Published: July 18, 2026*

---Read more

**Tags:** Lipfendra, enlicitide, PCSK9 inhibitor, cholesterol medication, FDA approval, LDL cholesterol, Merck, heart disease, statins, hypercholesterolemia, familial hypercholesterolemia, cardiovascular disease, cholesterol pill, oral PCSK9, Repatha, Praluent, Keytruda, cholesterol management, heart attack prevention

Citizens Bank Just Cut Ties with Private Prison Giants. Here’s Why That Matters.

Citizens Bank Just Cut Ties with Private Prison Giants. Here’s Why That Matters.

## A fierce six-month campaign of protests, divestment, and public pressure has forced one of the nation's largest banks to walk away from a multi-million dollar relationship. But the bank says it's just business.

---

### Introduction: The Bank That Said "Enough"

For over a decade, Citizens Bank had a quiet, profitable relationship with two of the largest private prison operators in the United States: CoreCivic and The GEO Group. These companies, which operate detention centers for U.S. Immigration and Customs Enforcement (ICE), had been reliable clients. CoreCivic had been with the bank since 2011, and GEO since 2018. It was a standard banking arrangement—credit facilities, financial services, the kind of thing that happens every day on Wall Street.

Then the protests began.

For six months, a coalition of activists, religious groups, and city governments waged a relentless campaign against Citizens Bank. They staged demonstrations outside branches, pressured customers to close their accounts, and convinced two New Jersey cities to withdraw nearly $356 million in deposits. They called it the "De-ICE Citizens Bank Coalition", and their message was simple: **stop financing human suffering.**

On July 17, 2026, Citizens Bank announced it would wind down its financial relationship with both CoreCivic and GEO Group. The bank said the decision was "purely for business reasons"—the companies' capital needs had changed because the federal government was buying some of their facilities. But the activists claimed victory, calling it "an important victory for the people who refused to let a major bank finance human suffering".

**This is the story of how a grassroots movement took on a $186 billion bank and won—and what it means for the future of corporate accountability.**

---

### The Players: Who Are CoreCivic and GEO Group?

To understand why this decision matters, you need to understand who these companies are.

**CoreCivic** and **The GEO Group** are the two largest private prison operators in the United States. They have dominated the industry for decades. At their peak in the early 2010s, they held more than 130,000 prisoners. Today, they remain the primary contractors for ICE detention centers and deportation operations.

Under President Trump's second term, both companies have seen their business boom. ICE contracts have expanded, and the companies have reported record revenue growth. In the second quarter of 2025 alone, CoreCivic reported $538 million in revenue, and GEO reported $636 million. They are, by any measure, extraordinarily profitable enterprises.

But they are also deeply controversial. Critics argue that private prisons incentivize incarceration, profit from human suffering, and operate with less accountability than public facilities. For the activists who targeted Citizens Bank, the issue was not just about the companies themselves—it was about the bank's role in financing them.

---

### The Campaign: How Activists Won

The campaign against Citizens Bank was a masterclass in grassroots organizing. Here's how it unfolded.

#### The Coalition

The De-ICE Citizens Bank Coalition brought together a diverse array of groups: religious organizations, immigrant rights advocates, community leaders, and concerned citizens. The Greater Boston Interfaith Organization played a prominent role, mobilizing congregations across the region. The coalition's message was framed in moral terms: "We refused to let a major bank finance human suffering".

#### The Protests

Activists staged demonstrations outside Citizens Bank branches in multiple states. In New Jersey, protests were held in five towns. In Boston, clergy and community leaders held vigils. The goal was to make the bank's relationship with CoreCivic and GEO impossible to ignore.

#### The Divestment

The coalition also targeted the bank's bottom line. They encouraged individuals, organizations, and municipalities to withdraw their money from Citizens. The results were significant:

| Entity | Amount Withdrawn |

|--------|------------------|

| Montclair, NJ | ~$91 million |

| Jersey City, NJ | ~$265 million |

| Individual customers and local organizations | ~$25 million |

| **Total** | **~$381 million** |

In total, more than **$380 million** was withdrawn from the bank in recent months because of its ties to the private prison industry. As one activist put it: "The financial pain has been growing almost daily".

#### The Victory

On July 17, the coalition declared victory. Citizens Bank announced it would exit its credit facilities with CoreCivic and GEO. The coalition called it "an important victory for the people". Rev. Ray Hammond of the Greater Boston Interfaith Organization said: "When people see a wrong being perpetrated, they can organize. They can build alliances and they can force big institutions and entities to do the right thing".

---

### The Bank's Response: "It's Just Business"

Citizens Bank has consistently denied that the decision was driven by political pressure. In a statement, the bank said the move was "purely for business reasons".

The bank's explanation is rooted in a changing financial landscape. The federal government has purchased several facilities owned by CoreCivic and is in talks to do the same with GEO. As a result, the companies' capital needs have been reduced, and they no longer require the full range of services Citizens provides.

"This is a business decision based on changed commercial circumstances and does not reflect any change in our view regarding these companies' business models or operations," the bank said.

Citizens also pushed back against the activists' characterization of the bank. In a statement on its investor website, the bank noted that it has "been disappointed that the activists have dragged it into what is largely a political matter". The bank emphasized its commitment to immigrant communities, citing $2 billion in community development funding and 140 nonprofit partners serving immigrant populations.

The bank also pointed to the regulatory environment. Under the Trump administration, bank regulators have been investigating "debanking" practices—the termination of banking relationships based on political considerations. The Office of the Comptroller of the Currency (OCC) has issued findings that called out reducing capital access to industries such as fossil fuels, gun manufacturers, and private prisons. Citizens noted that "all banks, including ourselves, must consider these regulatory and contractual frameworks in making decisions on who to bank or not bank".

---

### The Skeptics: Why the Coalition Isn't Fully Satisfied

Despite the victory, the De-ICE Citizens Bank Coalition is not entirely satisfied. The group is seeking written assurances that the bank is truly ending all banking relationships with CoreCivic and GEO.

The concern stems from the bank's statement, which referred to a federal requirement preventing it from denying services to businesses based on political considerations. The coalition worries that Citizens might maintain some indirect financial ties to the private prison industry.

"There's still work to be done to be absolutely certain that they are doing what they say they are doing," said Peyton Fleming, a spokesperson for the coalition.

---

### The Broader Context: A Wave of Divestment

Citizens Bank's decision is part of a larger trend. Several other major banks had already ended their relationships with private prison operators in 2019. Citizens was one of the holdouts—and now it has joined the majority.

The decision also comes amid a broader reckoning with the role of financial institutions in social and political issues. From fossil fuels to firearms to immigration detention, banks are increasingly being pressured to take a stand—or face the consequences.

The Trump administration has pushed back against this trend, launching investigations into "debanking" practices. But the Citizens case suggests that public pressure can still force change, even in a challenging political environment.

---

### The Human Element: What This Means for You

For the average American, this story is about more than just a bank and a few prison companies. It's about the power of collective action. It's about the idea that ordinary people—armed with conviction and a willingness to organize—can hold powerful institutions accountable.

**For the activist:** This is a victory—proof that six months of protests, divestment, and pressure can yield results. As Rev. Hammond said, "Democracy can work".

**For the bank customer:** This is a reminder that where you bank matters. Your deposits can be used to finance activities you may not support—or they can be withdrawn to send a message.

**For the investor:** This is a signal that environmental, social, and governance (ESG) considerations are not going away. Companies that ignore public pressure on social issues do so at their own risk.

**For the immigrant community:** This is a moment of relief—and a reminder that the fight is far from over. The detention centers still exist. The deportations continue. But one bank has stopped financing them.

---

### Frequently Asked Questions

**Q: Why did Citizens Bank cut ties with CoreCivic and GEO Group?**

A: Citizens Bank said the decision was based on "changed commercial circumstances"—the federal government is buying some of the companies' facilities, reducing their need for banking services. However, the decision came after months of public protests and pressure from activists.

**Q: What is the De-ICE Citizens Bank Coalition?**

A: It's a coalition of religious groups, immigrant rights advocates, and community organizations that campaigned for Citizens Bank to end its financial relationship with CoreCivic and GEO Group.

**Q: How much money was withdrawn from Citizens Bank during the campaign?**

A: More than **$380 million** was withdrawn, including $91 million from Montclair, NJ, $265 million from Jersey City, NJ, and $25 million from individual customers and local organizations.

**Q: Is Citizens Bank ending all relationships with CoreCivic and GEO?**

A: Citizens Bank said it will exit its credit facilities with both companies. However, activists are seeking written assurances that the bank is terminating all banking relationships.

**Q: What are CoreCivic and GEO Group?**

A: They are the two largest private prison operators in the United States. They contract with ICE to operate detention and deportation centers.

**Q: What is "debanking"?**

A: "Debanking" is the termination of banking relationships with businesses or individuals, often based on political or social considerations. The Trump administration has been investigating such practices.

**Q: Will this decision affect other banks?**

A: It's possible. Citizens was one of the last major holdouts among banks that financed private prisons. Its decision could increase pressure on other financial institutions to follow suit.

---

### Conclusion: A Victory, But Not the End

Citizens Bank's decision to cut ties with CoreCivic and GEO Group is a significant victory for the activists who campaigned for it. After six months of protests, divestment, and public pressure, one of the nation's largest banks has walked away from a multi-million dollar relationship.

But the activists themselves acknowledge that the fight is not over. The detention centers still operate. The deportations continue. And the coalition is seeking written assurances that the bank is truly ending all financial ties to the private prison industry.

For the rest of us, the Citizens Bank story is a powerful reminder that collective action can force change—even against powerful institutions. It's a testament to the idea that where we put our money matters, and that ordinary people can make a difference.

As Rev. Ray Hammond said: "When people see a wrong being perpetrated, they can organize. They can build alliances and they can force big institutions and entities to do the right thing".

The question now is: what will they organize for next?

---

### Disclaimer

**IMPORTANT:** This article is for informational and educational purposes only and does not constitute financial, investment, legal, or professional advice. The information contained herein is based on publicly available sources and reflects the author's understanding as of the publication date. The status of the relationships between Citizens Bank and CoreCivic and GEO Group, as well as the actions of the De-ICE Citizens Bank Coalition, are subject to change. You should consult with qualified professionals before making any decisions based on this information.

---

*Published: July 18, 2026*

Read more---

**Tags:** Citizens Bank, CoreCivic, GEO Group, private prisons, ICE, immigration detention, divestment, protest, banking, social responsibility, ESG, De-ICE Citizens Bank Coalition, grassroots activism, corporate accountability, debanking, Trump administration

Wall St Ends Lower for the Day and Week as Chip Selloff Broadens

  Wall St Ends Lower for the Day and Week as Chip Selloff Broadens

## The AI trade that powered the market for two years is facing its most serious test yet as semiconductor stocks enter bear-market territory.

---

### The Numbers: A Broad-Based Decline

Wall Street extended its decline on Friday, July 17, 2026, as a pullback in stocks associated with the AI boom—the very engine that drove most of the market's gains this year—morphed into a larger risk-off sentiment.

The final closing numbers told a story of a market under pressure:

| Index | Close | Change | % Change |

|-------|-------|--------|----------|

| **Dow Jones** | 52,146.42 | -406.55 | **-0.77%** |

| **S&P 500** | 7,457.69 | -76.08 | **-1.01%** |

| **Nasdaq Composite** | 25,520.24 | -361.70 | **-1.40%** |

The losses were broad-based, with all three major indexes closing lower on both the day and the week.The Nasdaq, home to the biggest AI and semiconductor names, bore the brunt of the selling, falling 1.4% on Friday and finishing the week down 2.9%—its worst weekly performance in months.

Semiconductor shares, which had led the broader market's moves in recent sessions, initially led the selloff. As the session progressed, the selling broadened beyond chips, pulling down even the Magnificent Seven tech giants.

### The Chip Bear Market: 20% Below the Peak

The Philadelphia Semiconductor Index (SOX) logged its steepest weekly loss in over a year, tumbling more than 18% so far in July.The index is now 20.2% below its June 22 record closing high, confirming that the semiconductor sector has officially entered bear-market territory.

Even with the steep declines, the SOX remains up nearly 65% year-to-date, compared with the S&P 500's roughly 9% gain.That's the paradox of this moment: the AI trade has been so powerful that even a bear-market correction leaves chip stocks with gains that would be the envy of any other sector. But for investors who bought at the peak, the pain is real.

### The Culprit: AI Spending Anxiety

So what's driving this selloff?

**The sustainability question.** Investors are increasingly worried about whether the nearly $1 trillion AI infrastructure spending boom can be sustained.Some active managers are already scaling back their exposure, according to a Reuters analysis, positioning for a potential slowdown in hyperscaler spending growth.

**The China AI threat.** The latest catalyst was the release of Kimi K3—a powerful new open-source AI model from Chinese startup Moonshot AI that performs on par with leading U.S. offerings.The development rattled U.S. firms, raising fears that Chinese AI could undercut sales and erode the competitive moat of American AI companies.

**The geopolitical jolt.** Escalating hostilities in the Iran war sent oil prices higher, fueling a risk-off mood across markets.Brent crude jumped another 4.6% on worries about the conflict, adding to the already anxious market sentiment.

**The fatigue factor.** As Ryan Detrick, chief market strategist at Carson Group, put it: "It's like the market has chip fatigue. Chip stocks are down three of the last four weeks, and it's the same worries, the same concerns; those stocks got way ahead of themselves, and now they're coming back to Earth."

### The Magnificent Seven: Not So Magnificent

Among the Magnificent Seven group of AI-related megacaps, all but Apple dipped on Friday, with Meta and Alphabet suffering the worst of it, down 2.7% and 3.2%, respectively.Alphabet's decline came on top of reports that its Gemini 3.5 Pro AI model launch was delayed, a sign that even the biggest players are struggling to execute in this hyper-competitive environment.

Nvidia, the chipmaker that has become the symbol of the AI boom, also slid as investors continued to rotate out of the artificial intelligence bellwether.

### The Bright Spots: Energy and Insurance

Not everything was red.

**Energy stocks** were the sole gainers among the major S&P 500 sectors, benefiting from spiking crude prices amid escalating hostilities in the Iran war.Brent crude jumped 4.6%, driving oil producers higher.

**Insurance stocks** also showed strength. The Travelers Companies jumped 9% after reporting a significant second-quarter earnings beat, with peers Progressive and Allstate also gaining.

And beneath the surface of the chip rout, the second-quarter earnings season is off to a surprisingly strong start. Of the 49 S&P 500 companies that have reported so far, 90% have delivered better-than-expected results, according to LSEG.Analysts now see year-on-year S&P 500 earnings growth of 26%, up from the 19.2% expectations at the start of the quarter.

### The Human Element: What This Means for Investors

**For the AI investor.** If you've been riding the AI wave, the last few weeks have been brutal. The chip index is down more than 18% in July alone. The Magnificent Seven are getting hammered. But the fundamental question remains: is this a healthy correction in a still-strong bull market, or the beginning of a more prolonged unwind?

**For the diversified investor.** This week's action is a reminder of why diversification matters. Energy stocks gained. Insurance stocks rallied. Even as tech cratered, other sectors held up. The investor who was spread across sectors weathered the storm far better than the one who was all-in on AI.

**For the long-term believer.** The AI revolution isn't over. Chip stocks are still up 65% year-to-date. The SOX is still up nearly 65% for the year.The selloff may be painful, but it's also a reminder that even the most powerful trends have corrections.

**For the skeptical observer.** The trigger for Friday's selloff—a new Chinese AI model—is a reminder that America's lead in AI is not unassailable. The gap is closing. And if Chinese models can match U.S. performance at a fraction of the cost, the entire pricing structure of the AI industry could be upended.

### Frequently Asked Questions

**Q: How much did the major indexes fall on Friday?**

The Dow fell 406.55 points (0.77%) to 52,146.42. The S&P 500 lost 76.08 points (1.01%) to 7,457.69. The Nasdaq Composite dropped 361.70 points (1.40%) to 25,520.24.

**Q: What happened to semiconductor stocks?**

The Philadelphia Semiconductor Index confirmed it is in bear-market territory, closing 20.2% below its June 22 record high.The index has tumbled over 18% so far in July.

**Q: Why are chip stocks selling off?**

Investors are worried about the sustainability of the nearly $1 trillion AI spending boom. A new open-source Chinese AI model that performs on par with U.S. offerings also rattled sentiment, as did escalating geopolitical tensions with Iran.

**Q: How did the Magnificent Seven perform?**

All but Apple dipped, with Meta down 2.7% and Alphabet down 3.2%.Alphabet was also hit by reports of a delay in its Gemini 3.5 Pro AI model launch.

**Q: Were there any gainers?**

Yes. Energy stocks were the sole gainers among S&P 500 sectors, benefiting from rising oil prices amid escalating Iran tensions.Insurance stocks also rallied, with Travelers jumping 9% after a strong earnings beat.

**Q: What were the weekly losses?**

The Nasdaq finished the week down 2.9%. The S&P 500 fell 1.6%. The Dow dropped 0.9%.

### Conclusion: A Market in Transition

The selloff on July 17, 2026, wasn't just another down day. It was a signal that the AI trade—the defining market narrative of the past two years—is facing its most serious test yet.

The chips are in bear market territory. The Magnificent Seven are under pressure. The Chinese are closing the gap. And investors are asking the question that, until now, they've been too euphoric to consider: *Is the AI spending boom sustainable?*

But it's also worth noting what didn't happen. The economy isn't collapsing. Earnings aren't cratering. In fact, 90% of S&P 500 companies that have reported so far have beaten expectations.The banks kicked off earnings season on a strong note.

What we're witnessing is a rotation, not a collapse. Money is moving out of the most overextended names and into sectors with better risk-reward profiles. Energy, insurance, and other value-oriented sectors are quietly gaining ground.

As Ryan Detrick put it: "Those stocks got way ahead of themselves, and now they're coming back to Earth."

The question for investors is whether this is a healthy correction in a bull market that still has room to run—or the beginning of something more painful. For now, the answer remains uncertain. What is certain is that the market's relationship with AI has fundamentally changed. The era of blind enthusiasm is over. The era of scrutiny has begun.

--Read more-

### Disclaimer

**IMPORTANT:** This article is for informational and educational purposes only and does not constitute financial, investment, or trading advice. The information contained herein is based on publicly available sources and reflects the author's understanding as of the publication date. Market conditions, stock prices, and economic data are subject to rapid change. Past performance is not indicative of future results. You should consult with a qualified financial advisor before making any investment decisions. The views expressed in this article are those of the author and do not constitute a recommendation to buy or sell any security.

This Is the Worst Week in Slop Bowl History

 This Is the Worst Week in Slop Bowl History

## From Chipotle to Chopt, cyclosporiasis is causing an implosion of sales—and an explosion in less pleasant places.

## Introduction: The Lunch Trend That Ran Into a Very Unpleasant Problem

For the better part of a decade, the "slop bowl" has been the undisputed king of the American lunch break. Chipotle, Sweetgreen, Cava, Chopt—these fast-casual chains built billion-dollar businesses on the promise of a quick, customizable, vaguely healthy meal served in a bowl. No bread, no fuss, just a pile of greens, grains, protein, and sauce that you could eat with a fork while scrolling through your phone. It was the perfect solution for the modern office worker.

Then came the diarrhea.

The cyclosporiasis outbreak of 2026 has turned the nation's favorite lunch into a game of gastrointestinal roulette. What started as a cluster of cases in the Midwest has ballooned into one of the largest foodborne illness outbreaks in recent U.S. history, with nearly 7,000 people affected across 34 states. The culprit? Shredded iceberg lettuce from Mexico, supplied to Taco Bell and distributed widely through the produce supply chain.

It's been the worst week in slop bowl history. And for the millions of Americans who rely on these chains for their daily lunch, it's raising an uncomfortable question: Is that bowl of greens worth the risk?

## The Numbers: A Crisis of Explosive Proportions

Let's start with the scale of the disaster. The numbers are staggering.

The Centers for Disease Control and Prevention has confirmed **1,645 lab-confirmed cases** of cyclosporiasis across 34 states, with more than **5,100 additional cases** under investigation. The true number of cases is almost certainly much higher, as many people who contract the parasite never seek medical attention.

Michigan has been the epicenter of the outbreak. The state has reported more than **5,000 cases** and **102 hospitalizations**. Ohio, Indiana, Kentucky, and West Virginia have also reported large numbers of cases.

| Location | Cases | Hospitalizations |

|----------|-------|------------------|

| **Michigan** | 5,000+ | 102 |

| **Ohio** | 1,192 | 86 |

| **Nationwide** | ~7,000 (confirmed + suspected) | 141+ |

The outbreak has been traced to shredded iceberg lettuce supplied by Taylor Farms, a California-based produce company, to Taco Bell restaurants. The lettuce was sourced from a single farm in central Mexico that represents less than 1% of the U.S. iceberg lettuce supply. But that small percentage has caused an outsized disaster.

Taco Bell's year-over-year sales growth slowed to just **4.2%** in the week ending July 11, the slowest rate since April. The chain has voluntarily removed the affected lettuce from its supply chain. But the damage to consumer confidence extends far beyond Taco Bell's drive-thrus.

## The Domino Effect: An Industry in Panic

The cyclosporiasis outbreak has triggered a wave of selling across the fast-casual restaurant sector, hitting chains that haven't even been linked to the outbreak.

**Sweetgreen**, whose menu is centered around raw vegetables, has seen its stock tank **over 24% in the last month**. The company's shares fell **5.6%** on Wednesday alone—even though no cases have been linked to the salad chain.

**Chipotle** dropped nearly **5%** on Wednesday, even though the company said it doesn't believe its ingredients are associated with the outbreak. "We are aware of the Cyclospora investigation and at this time, we don't believe the ingredients we source are associated," said Laurie Schalow, Chipotle's chief corporate affairs and food safety officer.

**Cava** and other bowl-based chains have also taken hits. Investors are spooked, and the market is punishing any company that relies on fresh produce—especially lettuce.

As Zak Stambor, an analyst at eMarketer, put it: *"Perception matters as much as the facts in the early stages of a food safety investigation. Even an unconfirmed link to a foodborne illness can cause consumers to rethink where they eat"*.

## What Is Cyclosporiasis? The Parasite That's Ruining Lunch

Cyclosporiasis is an intestinal illness caused by the microscopic parasite *Cyclospora cayetanensis*. People become infected by consuming food or water contaminated with the parasite, typically fresh produce like raw fruits and vegetables. It is not spread from person to person.

The symptoms are as unpleasant as you'd imagine. According to the CDC, they include:

- **Frequent, watery diarrhea** (sometimes explosive)

- **Loss of appetite and weight loss**

- **Abdominal cramps and bloating**

- **Nausea and fatigue**

- **Low-grade fever** (rarely)

Symptoms typically begin about **one week after exposure** and can last for weeks or even months if untreated. The recommended treatment is a 7-10 day course of the antibiotic trimethoprim-sulfamethoxazole (Bactrim or Septra).

## The Source: A Single Farm, a Nationwide Crisis

The FDA's traceback investigation identified shredded iceberg lettuce from a single farm in central Mexico as the source of the outbreak. The lettuce was supplied by Taylor Farms, a California-based produce company, to Taco Bell restaurants in five states: Indiana, Kentucky, Michigan, Ohio, and West Virginia.

Taylor Farms has responded by **voluntarily removing all iceberg lettuce sourced from central Mexico** from the U.S. market indefinitely. The company said the affected farm represents less than 1% of the U.S. iceberg lettuce supply, but that it was removing all lettuce from the region out of an abundance of caution.

> *"As a family-owned company, we are deeply concerned for those who became ill, their families, and the Americans whose trust in the safety of fresh produce has been shaken. We are committed to doing everything in our power to address this issue, support the ongoing investigation, and help restore trust"*.

Taco Bell has also taken action. The chain has removed the affected lettuce from its supply chain in select states. *"While no official advisory has been issued, we believe public health is a shared responsibility among restaurants, their suppliers, and authorities,"* a spokesperson said.

## The Slop Bowl's Resilience: Will Americans Change Their Habits?

The big question now is whether the outbreak will permanently change American eating habits.

The "slop bowl" has been one of the most successful food trends of the past decade. Chains like Chipotle, Sweetgreen, Cava, and Chopt have built empires on the premise that Americans want a customizable, healthy-ish meal that they can eat quickly and feel good about. But that premise depends on trust—trust that the ingredients are safe, that the supply chain is secure, and that the bowl you're eating won't send you to the hospital.

*"The slop bowl is resilient, if nothing else,"* wrote Business Insider's Juliana Kaplan. In an informal poll of New Yorkers, some were unaware of the outbreak entirely, while others were willing to risk it. *"But for office lunch ... I'm going a little bit more rogue here,"* one office worker told Kaplan as he ate a fast-casual Mediterranean salad.

But history suggests that food safety crises can have long-lasting effects. After Chipotle's 2015 E. coli outbreak, the chain struggled for years to regain customer trust. It eventually paid a **$25 million fine** and agreed to a new food safety plan. The company's stock took years to recover.

## The Trump Administration's Role

The outbreak has also raised questions about the Trump administration's handling of public health. As Slate noted, the administration's "self-sabotaged public health apparatus" has made it harder to respond to foodborne illness outbreaks. The CDC's ability to track and respond to outbreaks has been hampered by staffing cuts and political interference, critics say.

The CDC has confirmed 1,645 cases and is investigating more than 5,100 additional cases. But the agency's data lags far behind state health departments. Michigan alone has reported more than 5,000 cases. The true scale of the outbreak may never be known.

## Frequently Asked Questions

### Q: What is cyclosporiasis?

Cyclosporiasis is an intestinal illness caused by the microscopic parasite *Cyclospora cayetanensis*. People become infected by consuming food or water contaminated with the parasite, typically fresh produce like raw fruits and vegetables.

### Q: What are the symptoms?

Symptoms include frequent, watery diarrhea (sometimes explosive), loss of appetite, weight loss, abdominal cramps, bloating, nausea, and fatigue. Symptoms typically begin about one week after exposure.

### Q: How is it treated?

The recommended treatment is a 7-10 day course of the antibiotic trimethoprim-sulfamethoxazole (Bactrim or Septra).

### Q: Which restaurants are affected?

Taco Bell has been linked to the outbreak in five states: Indiana, Kentucky, Michigan, Ohio, and West Virginia. However, the lettuce supply chain extends to other restaurants and grocery stores, and the investigation is ongoing.

### Q: Is it safe to eat at Chipotle or Sweetgreen?

Both chains have said they don't believe their ingredients are associated with the outbreak. However, the broader concern about fresh produce has led to stock declines and consumer anxiety.

### Q: Should I stop eating salad?

Health experts recommend washing all produce thoroughly under running water. The only sure-fire way to kill the parasite is to cook vegetables to 158 degrees Fahrenheit. If you're concerned, consider avoiding raw produce until the source of the outbreak is fully contained.

### Q: How many people have been affected?

Nearly 7,000 people have been affected across 34 states. The CDC has confirmed 1,645 cases and is investigating more than 5,100 additional cases.

### Q: What should I do if I think I have cyclosporiasis?

Contact your healthcare provider. Cyclosporiasis is treatable with antibiotics, but it can cause severe dehydration if left untreated.

## Conclusion: The Week That Changed Lunch Forever

The cyclosporiasis outbreak of 2026 has been a wake-up call for the American restaurant industry. The "slop bowl" empire, built on the promise of quick, healthy, customizable meals, has been shaken to its core. A single farm in Mexico—representing less than 1% of the U.S. iceberg lettuce supply—has caused a nationwide crisis that has sickened nearly 7,000 people and wiped billions off the market value of restaurant chains.

The outbreak has exposed the fragility of the modern food supply chain. The same efficiencies that allow a single farm to supply lettuce to thousands of restaurants also mean that a single contamination event can cause a nationwide disaster. The industry's reliance on mass-processed salad mixes has made it vulnerable to a parasite that thrives in the gaps of the system.

For consumers, the message is clear: the slop bowl may be convenient, but it's not risk-free. For restaurant chains, the message is even starker: trust is hard to earn and easy to lose. As the industry struggles to contain the fallout, one thing is certain: the worst week in slop bowl history is a lesson that won't be forgotten anytime soon.

--Read more-

## Disclaimer

**IMPORTANT:** This article is for informational and educational purposes only and does not constitute medical advice. If you suspect you have cyclosporiasis or are experiencing symptoms, contact a healthcare provider immediately. The information contained herein is based on publicly available sources and reflects the author's understanding as of the publication date. The cyclosporiasis outbreak is ongoing, and case counts, affected areas, and restaurant responses are subject to change.

🍦 National Ice Cream Day 2026: The Ultimate Guide to Free Scoops, Sweet Deals, and Irresistible

  🍦

National Ice Cream Day 2026: The Ultimate Guide to Free Scoops, Sweet Deals, and Irresistible Offers

**Mark your calendars, ice cream lovers—Sunday, July 19, 2026, is National Ice Cream Day! Here's your complete guide to scoring free cones, BOGO deals, and mouthwatering discounts across the country.**

---

## Introduction: The Sweetest Day of the Year Is Almost Here

As summer temperatures continue to soar and the nation swelters under a relentless heatwave, there's one day that promises sweet relief: **National Ice Cream Day**. Celebrated every year on the third Sunday of July, this year the holiday falls on **July 19, 2026**. And the best part? Ice cream shops, fast-food chains, and retailers across the country are rolling out the red carpet with free scoops, buy-one-get-one offers, and exclusive discounts.

Originally established by President Ronald Reagan in 1984, National Ice Cream Day has become one of America's most beloved food holidays. Whether you're craving a classic cone, a decadent sundae, or a frozen treat for your furry friend, there's a deal out there with your name on it. From Friendly's no-strings-attached free cone to Dippin' Dots' nationwide giveaway, this year's lineup is one of the best in recent memory.

Here's everything you need to know to make the most of National Ice Cream Day 2026.

---

## 🎁 The Best Freebies: Zero Purchase Required

Let's start with the deals that require absolutely **no purchase**—just show up and enjoy.

### Friendly's: Free Cone or Dish — No Purchase, No Membership, No Fine Print

**Friendly's** is keeping things simple and, well, friendly. On July 19, every guest can enjoy a **free cone or dish** of their signature ice cream at participating locations nationwide. No rewards membership is required. No purchase is necessary. No fine print. Just pure, unadulterated ice cream bliss. The chain expects to draw around **100,000 guests systemwide**, handing out **12,000 to 15,000 free scoops** coast to coast.

This is the gold standard of National Ice Cream Day freebies—a genuine, no-strings-attached gift from one of America's most beloved ice cream chains.

### Dippin' Dots: Free Mini Cup at 128 Locations Nationwide

**Dippin' Dots**, the original beaded ice cream, is celebrating in a big way. On July 19, fans can enjoy a **free mini cup** at participating locations nationwide, including all **128 Dippin' Dots franchise locations**. No purchase is necessary.

**Important note:** The free giveaway occurs during a **specific two-hour window** at each location, so be sure to check the [Dippin' Dots locator](https://www.dippindots.com/locator) to find a participating store near you and confirm the exact timing.

**Bonus:** You can also enter for a chance to win **free Dippin' Dots for a year**—a first for the brand's National Ice Cream Day celebration.

### 16 Handles: Free Froyo (Up to $5) with App Download

Frozen yogurt fans, rejoice! **16 Handles** is offering customers **up to $5 of free froyo** on July 19—all you have to do is download the app and register. It's a sweet deal for anyone who prefers their frozen treat swirled, not scooped.

### Chuck E. Cheese: Free Dippin' Dots with Digital Coupon

Bring the kids (or embrace your inner child) to **Chuck E. Cheese** on July 19. With a digital coupon available at [chuckecheese.com/ICECREAMDAY2026](https://www.chuckecheese.com/ICECREAMDAY2026), you can redeem a **free serving of the exclusive Chuck E.'s Cookie Crunch flavor**. It's a fun way to celebrate the holiday with the family.

---

## 💰 Deals with a Small Catch: Spend a Little, Save a Lot

Not every deal is completely free, but these offers require only a minimal purchase to unlock significant savings.

### Dairy Queen: Free Dilly Bar with $1+ Purchase

**Dairy Queen** is celebrating National Ice Cream Day all week long. From **July 13 through July 19**, DQ Rewards members can get a **free Dilly Bar** with any purchase of **$1 or more** in the DQ app. The offer is limited to one per rewards member.

The fan-favorite Dilly Bar features vanilla soft serve shaped into a round bar, placed on a stick, and dipped in a crunchy flavored coating. It's a classic treat that's hard to beat—especially when it's free.

### Wendy's: $1 Small Frosty (Available In-App)

**Wendy's** is offering a **$1 small Classic Frosty** on National Ice Cream Day through the Wendy's app. You can choose between classic chocolate or vanilla. For Frosty fans, this is an unbeatable price for one of America's favorite fast-food desserts.

**Also available:** Wendy's Rewards members can also get a **free Frosty with a $20+ order** through DashPass from July 16-22.

### Del Taco: BOGO Milkshakes for Rewards Members

**Del Taco** is giving its Del Yeah! Rewards members a **buy-one-get-one-free deal on regular shakes** from July 17 through July 19. The offer is available in classic flavors at participating locations.

---

## 🏪 Grocery & Retail Deals: Stock Up on Pints and More

If you prefer to enjoy your ice cream at home, these grocery and retail deals are for you.

### GoPuff: Ben & Jerry's 2 for $8, Halo Top 2 for $10, and More

**GoPuff** is celebrating all week long with discounts on frozen treats from **July 13 through July 19**. Deals include:

- **Two Ben & Jerry's pints for $8**

- **Two Halo Top pints for $10**

- **30% off Snickers and Twix ice cream bar multipacks**

- **FAM members**: Select premium pints (Magnum, Ben & Jerry's, Breyer's) for just **$3.50**

### Blue Bunny: Buy 2, Save $5 on DoorDash's DashMart

Through **July 26**, you can use DoorDash's grocery extension, DashMart, to score a **"buy two, save $5" deal** on Blue Bunny soft pints and mini swirls.

### Cold Stone Creamery: $5 Off $10+ with Text Code

**Cold Stone Creamery** is celebrating ice cream all month long. Through **July 31**, My Cold Stone Reward members can get **$5 off $10+** by texting **"LOVEIT26"** to **568348**. New reward members in July also receive an **additional $5 reward**.

**Bonus:** Follow Cold Stone on Instagram for a chance to win ice cream for a year (a $450 e-gift card), hoodies, hats, and tote bags.

### Graeter's: 10% Off Online Orders with Code

**Graeter's** is offering **10% off all online orders** from July 17 through July 19. Use the code **ICECREAMDAY10** at checkout. Sweet Rewards members can also grab a **$1.56 single-dip sugar cone** in-store.

### Stop & Shop: Free 1.5-Quart Ice Cream for GO Rewards Members

From **July 13 through July 23**, Stop & Shop GO Rewards members who check in at in-store Savings Station kiosks can receive a **free 1.5-quart container** of Stop & Shop ice cream.

---

## 📱 App & Delivery Deals: Order In and Save

For those who prefer to stay cool indoors, these app-based and delivery deals are perfect.

### Baskin-Robbins: $5 Off $20+ Orders (July 19-25)

**Baskin-Robbins** rewards members can snag a sweet deal beginning on National Ice Cream Day and lasting until **July 25**—**$5 off an order of $20 or more** when using the app or website. Then, on **July 26**, members can also get a **buy-one-get-one free scoop**.

### Insomnia Cookies: Free Two-Scoop Cup with $5+ Purchase

Yes, Insomnia Cookies specializes in cookies, but they also serve ice cream—and they're honoring National Ice Cream Day from **Friday, July 17, through Sunday, July 19**. Customers can receive a **free two-scoop cup of ice cream** with the purchase of at least $5. No Insomnia Cookie Rewards membership is required.

### DoorDash DashPass: Free Frosty with $20+ Order, Buy 2 Save $4 on Häagen-Dazs

**DashPass members** get sweet deals from July 16-22 in honor of National Ice Cream Day:

- **Free Wendy's Frosty** with a **$20+ order**

- **Buy two, save $4** on Häagen-Dazs

- Additional deals at Starbucks and Tropical Smoothie Cafe as part of DoorDash's "Summer of DashPass" promotion

### Häagen-Dazs: Buy 2, Save $4 for DashPass Members

Through **July 22**, DashPass members can buy **two Häagen-Dazs products and save $4**.

### Carvel: Win a Free Carvelanche by Sharing Your "Dessert Disaster"

**Carvel** is turning dessert fails into free ice cream. Through **July 24**, customers can upload a photo of a disappointing frozen dessert to Carvel's **Dessert Disaster campaign**. Five hundred winners will receive a gift card for a **free Carvelanche**—Carvel's signature blended soft-serve dessert packed with mix-ins.

---

## 🐾 Deals for Your Furry Friends: Yes, Dogs Get Ice Cream Too!

National Ice Cream Day isn't just for humans. Your four-legged family members can join the celebration too!

### Petco: Free Ben & Jerry's Doggie Dessert for Petco Perks Members

**Petco Perks members** can grab a **free Ben & Jerry's Doggie Dessert** for their pups while supplies last. It's the perfect way to include your furry best friend in the festivities.

---

## 🏆 Sweepstakes & Giveaways: Win Ice Cream for a Year

Several brands are offering the chance to win free ice cream for an entire year—and more.

### Bruster's Ice Cream: Win Free Ice Cream for a Year

All Bruster's locations are participating in a sweepstakes in honor of National Ice Cream Month. From now through **July 31**, you can fill out a form for a chance to be one of **10 lucky winners** who will win **free ice cream for an entire year**.

### Dippin' Dots: Win Free Dippin' Dots for a Year

For the first time as part of National Ice Cream Day, Dippin' Dots is offering one lucky fan the chance to win **free Dippin' Dots for a year**. Enter at DippinDots.com/NICD.

### Cold Stone Creamery: Ice Cream Week Giveaway

Enter Cold Stone's **Ice Cream Week Giveaway** through Instagram or email for a shot at winning prizes like e-gift cards and merchandise. The daily sweepstakes ends **July 22 at 11:59 p.m. Mountain time**.

### Marble Slab Creamery: Instagram Sweepstakes

Marble Slab Creamery is running an Instagram sweepstakes all month long. Each week, the company is giving away **$50 Marble Slab Creamery gift cards**. The giveaway ends **July 31 at 5 p.m. Eastern time**.

---

## 📋 Quick Reference: Your National Ice Cream Day Cheat Sheet

| Brand | Deal | When | Requirements |

|-------|------|------|--------------|

| **Friendly's** | Free cone or dish | July 19 | No purchase, no membership |

| **Dippin' Dots** | Free mini cup | July 19 (2-hour window) | No purchase; check locator |

| **16 Handles** | Free froyo (up to $5) | July 19 | Download app |

| **Dairy Queen** | Free Dilly Bar | July 13-19 | $1+ purchase in app |

| **Wendy's** | $1 small Frosty | July 19 | App purchase |

| **Del Taco** | BOGO milkshakes | July 17-19 | Rewards membership |

| **Baskin-Robbins** | $5 off $20+ | July 19-25 | Rewards membership |

| **Cold Stone** | $5 off $10+ | Through July 31 | Text "LOVEIT26" to 568348 |

| **Insomnia Cookies** | Free 2-scoop cup | July 17-19 | $5+ purchase |

| **GoPuff** | 2 pints Ben & Jerry's for $8 | July 13-19 | No membership required |

| **Petco** | Free doggy ice cream | July 19 | Petco Perks membership |

| **Carvel** | Free Carvelanche | Through July 24 | Submit dessert fail photo |

---

## 🍦 Pro Tips for National Ice Cream Day

1. **Check local participation:** Not all locations may be participating, so it's always a good idea to call ahead or check the brand's website before heading out.

2. **Download apps in advance:** Many deals require app downloads or rewards membership. Save yourself time on the day by setting up your accounts now.

3. **Follow social media:** Many brands are running Instagram giveaways and posting real-time updates. Follow your favorite ice cream shops for the latest news.

4. **Bring the whole family—including the dog!** Petco's free doggy ice cream means no one gets left out.

5. **Plan your route:** With so many deals available, consider mapping out a route that hits multiple participating locations for maximum ice cream enjoyment.

---

## Conclusion: A Day of Sweet Indulgence Awaits

National Ice Cream Day 2026 is shaping up to be one of the sweetest yet. From Friendly's no-strings-attached free cone to Dippin' Dots' nationwide giveaway, there's never been a better time to indulge your sweet tooth.

Whether you're a classic cone purist, a froyo fanatic, or someone who believes ice cream is better when it comes in tiny beaded form, this Sunday has something for everyone. And with deals ranging from completely free to incredibly cheap, you can satisfy your cravings without breaking the bank.

So mark your calendars for **July 19, 2026**, rally your friends and family (and your dog!), and get ready to celebrate one of America's most beloved food holidays. After all, as the old saying goes: *I scream, you scream, we all scream for ice cream!*

---

## Disclaimer

**IMPORTANT:** This article is for informational and educational purposes only. All deals, promotions, and offers mentioned are based on publicly available sources and are subject to change without notice. Participation may vary by location, and some offers may require app downloads, rewards membership, or minimum purchases. Please verify details directly with the respective brands before visiting. This article does not constitute an endorsement of any product, brand, or service. Ice cream consumption should be enjoyed responsibly as part of a balanced diet.

---

*Published: July 18, 2026*

--Read more-

**Tags:** National Ice Cream Day 2026, free ice cream, ice cream deals, July 19 2026, Friendly's free cone, Dippin' Dots free ice cream, Dairy Queen Dilly Bar, Wendy's $1 Frosty, Baskin-Robbins deals, Cold Stone Creamery, GoPuff ice cream deals, Petco doggy ice cream, ice cream freebies, National Ice Cream Day promotions, summer treats